
GLP-1 weight-loss drug boom pushes employers to rethink coverage
Rising use of GLP-1 weight‑loss drugs is driving higher employer healthcare costs, with about two‑thirds of U.S. companies currently covering GLP-1s for weight loss but around 10% planning to drop coverage next year; PepsiCo, Cigna and Starbucks have already limited or ended coverage, while Bank of America’s Moynihan says GLP-1 spending is large yet beneficial for employees, highlighting a broader debate on affordability and value as plans seek sustainability.









